Phase III trial Archives - Journal for Clinical Studies

Current Edition

news

Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a f...

24 January 2018 news enrollment | liver cancer

Continue Reading →

news

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Fortuna Fix, a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient's own neural stem cells (autologous) p...

8 November 2017 news clinical | neurotrauma

Continue Reading →

news

New Phase 2 Data Show Treatment With Tremfya® (Guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year

Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA® (guselkumab), the first selective an...

7 November 2017 news arthritis | Phase III trial

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Rare Disease Ebook

Decentralised Clinical Trials in The EU

RWS – eBook

It’s All About Stem Cells

Covid-19

Current Edition

Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

New Phase 2 Data Show Treatment With Tremfya® (Guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year

Journal for Clinical Studies